Volume -
3 , - : 447-452 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Relationship of Hospitalized COVID-19 Patients and Thyroid Dysfunction. 3 https://doi.org/10.58209/ijwph.15.4.447
URL: http://daneshafarand.org/article-1-85564-en.html
URL: http://daneshafarand.org/article-1-85564-en.html
Abstract: (1527 Views)
Aims: Although vaccines have been developed for COVID-19, the virus continues to present problems to the health sector. The current study assessed thyroid function in all hospitalized patients diagnosed with the virus to ascertain whether COVID-19 infection was linked to thyroid function abnormalities.
Instrument & Methods: An observational cohort study was conducted on all COVID-19-positive patients hospitalized in the Al-Fourat Al-Awsat Hospital in Al-Kufa, Iraq, between September 2021 and April 2022. 208 potential patients were tested during this period, and 150 COVID-19 patients and 50 COVID-19-negative individuals were selected. A sample of blood was collected during hospitalization. A serum was used to determine the thyroid-stimulating hormone.
Findings: Hypertension, shortness of breath, diabetes, liver dysfunction, and cardiac and pro-inflammatory diseases were the most frequent comorbidities in COVID-19 patients. The association between COVID-19 and Control groups indicated a significant difference in age, body mass index, gender, systolic- and diastolic blood pressure, fasting blood sugar, HbA1C, alanine aminotransferase, and aspartate aminotransferase. Also, the analysis indicated a significant (p<0.001) difference between COVID-19 patients and the control group in the level of TSH.
Conclusion: Thyroid impairment is frequent in most individuals admitted to the hospital with a COVID-19 infection. Low thyroid-stimulating hormone level is a reliable indicator of poor prognosis in COVID-19-infected individuals.
Instrument & Methods: An observational cohort study was conducted on all COVID-19-positive patients hospitalized in the Al-Fourat Al-Awsat Hospital in Al-Kufa, Iraq, between September 2021 and April 2022. 208 potential patients were tested during this period, and 150 COVID-19 patients and 50 COVID-19-negative individuals were selected. A sample of blood was collected during hospitalization. A serum was used to determine the thyroid-stimulating hormone.
Findings: Hypertension, shortness of breath, diabetes, liver dysfunction, and cardiac and pro-inflammatory diseases were the most frequent comorbidities in COVID-19 patients. The association between COVID-19 and Control groups indicated a significant difference in age, body mass index, gender, systolic- and diastolic blood pressure, fasting blood sugar, HbA1C, alanine aminotransferase, and aspartate aminotransferase. Also, the analysis indicated a significant (p<0.001) difference between COVID-19 patients and the control group in the level of TSH.
Conclusion: Thyroid impairment is frequent in most individuals admitted to the hospital with a COVID-19 infection. Low thyroid-stimulating hormone level is a reliable indicator of poor prognosis in COVID-19-infected individuals.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |